Inflammatory Disease of the Central Nervous System

Patricia J. Luttgen, DVM, MS

"Encephalitis," "myelitis," and "meningitis" are terms applied to inflammatory conditions of the brain, spinal cord, and meninges, respectively. Because of the close anatomic proximity of these central nervous system (CNS) structures, inflammatory processes frequently involve more than one of them at a time. Thus, the terms "encephalomyelitis," "meningoencephalitis," and "meningoencephalomyelitis" may apply. One should approach any suspected CNS inflammatory problem as having the potential to become widespread (multifocal or diffuse) if it has not done so already.

In general, the majority of CNS inflammatory diseases present in an acute progressive manner; a more insidious onset is possible. Fungal diseases prove the most consistent exception, more commonly presenting with chronic progressive signs. Whenever rapidly developing and spreading dysfunction of the CNS is observed, inflammatory conditions must be considered at the top of the list of differential diagnoses.

CLINICAL SIGNS

The presenting complaints and clinical signs seen in inflammatory diseases of the CNS are highly variable, because all parts of the CNS are susceptible to inflammatory processes. Some etiologic agents have predispositions to particular areas of the CNS (such as canine distemper virus to the cerebellum) but cannot be relied upon to consistently involve those areas in each case. Neurologic dysfunction may be focal, multifocal, or diffuse in nature. Because of the rapidly progressive nature of many of these diseases, an initial focal localization may progress to multifocal or diffuse in a relatively short period of time.

*Diplomate, American College of Veterinary Internal Medicine (Neurology); Associate Professor, Neurology and Neurosurgery, Department of Small Animal Medicine and Surgery, Texas A&M University College of Veterinary Medicine, College Station, Texas
The predominant clinical signs in viral, protozoal, and parasitic diseases relate to parenchymal involvement of the brain and/or spinal cord. Rickettsial and fungal diseases may display parenchymal as well as meningeal signs. Bacterial diseases most commonly present with meningeal signs, which may spread to display parenchymal signs.

Encephalitis and Myelitis

Although clinical signs are highly variable in cases of encephalitis, some generalities can be made. Signs usually reflect diffuse brain parenchymal involvement that may be slightly asymmetric. Common clinical signs seen in encephalitis include altered states of consciousness (depression, stupor, and so forth), behavioral changes, visual impairment with intact pupillary light reflexes, incoordination, voluntary motor dysfunction, and cranial nerve dysfunction. Sometimes seizures may be a part of the history.

Myelitis occurs more frequently in association with encephalitis (encephalomyelitis). However, the spinal cord parenchyma may be involved in an inflammatory process without associated brain involvement. The clinical signs seen will depend on the location and extent of involvement. Spinal cord signs of sensory ataxia, depressed postural reactions, motor dysfunction, and possibly loss of pain sensation may occur in one or more limbs. Urinary and fecal incontinence may also be present.

Meningitis

Classically, two major clinical signs accompany meningitis: neck pain and fever. Afflicted animals are usually reluctant to be handled around the neck, displaying cervical hyperesthesia and muscle rigidity. Meningeal irritation may be sufficient to cause opisthotonus and forelimb hyperextension. Generalized hyperesthesia may also be present. Meningitis is usually accompanied by some degree of parenchymal involvement (encephalomyelitis) that may or may not be clinically evident.

Meningitis is not a common disease problem of companion animals. In bacterial meningitis, organisms gain access to the subarachnoid space through hematogenous spread, direct extension from the sinuses, ears, and eyes, penetrating trauma, and contaminated surgical instruments, including spinal needles. Once established, the inflammatory process usually spreads to involve parenchymal structures (meningoencephalomyelitis). Fungal organisms usually reach the CNS via hematogenous or lymphatic routes but may also arrive via direct extension from adjacent infections, as in fungal sinusitis. Rickettsial organisms infrequently involve the nervous system but may cause signs suggestive of meningitis (fever, hyperesthesia) along with signs of parenchymal involvement (depression, paresis, seizures, and so forth). Suspected immune-mediated meningitis and meningitis/vasculitis have also been reported. Viral, protozoal, and parasitic diseases primarily affect parenchymal tissues with associated meningeal reaction. Clinical signs in these conditions are more typical of encephalitis and/or myelitis than meningitis.
INFLAMMATORY DISEASE OF THE CENTRAL NERVOUS SYSTEM

DIAGNOSTIC PROCEDURES

Minimum Database

In cases of suspected CNS inflammatory disease, the diagnostic plan should begin with a neurologic minimum database (MDB). This should include complete physical and neurologic examinations with special attention paid to the ophthalmic and otic examinations. In addition, an electrocardiogram should be included in preparation for the anesthesia necessary to collect cerebrospinal fluid (CSF). Laboratory tests should include a complete blood count (CBC), blood chemistry profile including electrolytes, urinalysis, and fecal analysis. Choice of additional laboratory tests will be based on the MDB results.

**Laboratory Tests.** The MDB evaluates the general health of the animal, including the nervous system. Multisystemic involvement is often reflected in abnormal physical and laboratory findings. Knowing the organ system preferences of various etiologic agents helps the clinician formulate a reasonable differential list based on MDB abnormalities as well as identify additional tissues for possible culture.

In many animals, the inflammatory process will not extend outside the CNS. In these cases, it is not unusual for the MDB laboratory results to be totally normal. The nervous system is very effectively isolated from other organ systems by the blood-brain, blood-CSF, CSF-extracellular fluid, blood-eye, and blood-nerve barriers. Even though we normally assume these barriers are compromised in CNS inflammatory processes, that does not mean disease processes will be reflected in the MDB laboratory results. In my experience, animals with primary CNS inflammatory disease usually have normal MDB laboratory results (with the notable exception of feline infectious peritonitis [FIP]), requiring additional diagnostic tests to make the diagnosis.

**Ophthalmic and Otic Examinations.** The ophthalmic and otic examinations are especially important in suspected cases of CNS inflammatory disease. Because the optic nerve extends directly from the brain, papilledema or optic neuritis may reflect a larger inflammatory process in the CNS. Many of the organisms that cause CNS inflammation also cause ocular lesions. Evidence of acute chorioretinitis, granulomatous chorioretinitis, vasculitis, retinal hemorrhage, retinal detachment, uveitis, corneal edema, keratitis, and conjunctivitis can assist greatly in ruling out possible etiologic agents.95

The ear is one of the most common sites of entry of organisms into the CNS. Otitis externa is extremely common in dogs and can extend to become otitis media/interna with subsequent invasion of the CNS. Oropharyngeal inflammation may also extend, causing otitis media/interna. Any signs of otitis should be investigated thoroughly in animals displaying CNS inflammatory disease.

**Cerebrospinal Fluid**

Cerebrospinal fluid analysis is the single most important diagnostic test that can be performed on animals suspected of having a CNS inflammatory disease. Even so, it is possible to have false-negative results or misleading...
cellular populations. Great caution must be exercised in collecting fluid because of the potential dangers of anesthesia, tentorial herniation, and spread of infection.60

**Risks of CSF Collection.** Collection of CSF in companion animals requires general anesthetic restraint, which always entails some risks. When an animal has encephalitis, the risks are compounded by potential involvement of the respiratory centers of the brain stem and the reticular activating system. Encephalitic animals often present with already altered states of consciousness and are therefore much more susceptible to anesthetic accidents. Great care must be taken in administering and monitoring anesthesia in animals with encephalitis.

Encephalitis causes cerebral edema, which leads to increased intracranial pressure. When CSF is removed, the ventricular volume and, thus, intracranial pressure is reduced, allowing the parenchyma to swell further. If the intracranial pressure is sufficiently increased when CSF is removed, the cerebral hemispheres and cerebellum will move caudally under the tentorium cerebelli and through the foramen magnum, respectively, causing midbrain and medullary brain-stem compression. This is a life-threatening condition unless corrected immediately.

Clinical signs suggestive of increased intracranial pressure include altered mentation, altered pupillary size and responsiveness, poor to absent eye movements in response to alterations in head position (physiologic/vestibular nystagmus), motor dysfunction, and abnormal respiratory patterns. If increased intracranial pressure is suspected, CSF collection should be delayed while attempts are made to therapeutically reduce the pressure. Drugs that have proved helpful in reducing cerebral edema are osmotic diuretics, glucocorticoids (generally contraindicated in CNS inflammatory disease), dimethylsulfoxide, barbiturates, nonsteroidal analgesics, antifibrinolytic agents, antibiogenic amine compounds, endorphin antagonists, and blood flow stimulants.73 These same drugs are advocated when tentorial herniation is suspected. Improvement in clinical signs indicates response to therapy, at which time a decision on CSF collection can be made. Fortunately, in most cases of inflammatory CNS disease, intracranial pressure is not elevated significantly enough to prevent collection and analysis of CSF.72

Collection of CSF may hasten the spread of an inflammatory process by altering CSF flow dynamics. During CSF collection, fluid is withdrawn at a rate faster than the normal flow rate of CSF through the ventricles, subarachnoid space, and central spinal canal. If the causative agent is present in the CSF, its movement through the CNS may be hastened. Also, the meninges may become contaminated secondary to the spinal tap.

**CSF Collection.** CSF is most commonly collected from the cisterna magna (cerebellomedullary cistern), which provides the largest, most easily accessible reservoir of CSF in companion animals. Even so, care must be exercised during placement of the spinal needle or puncture of the medullary brain stem may occur, causing death subsequent to respiratory failure. If fluid is withdrawn too rapidly from the cisterna, tentorial herniation may occur. An advisable rate of removal is no faster than 1 ml per 30-second interval.60 Lumbar subarachnoid puncture is extremely
difficult to perform and often does not yield adequate volumes for analysis. In addition, CSF collected from the lumbar subarachnoid space has been shown to differ in protein and cellular content from fluid collected from the cisterna magna, which could complicate interpretation. 3

Collection of CSF should always be performed in an aseptic manner. Sternal or lateral positioning of the animal is determined by personal preference if the fluid is aspirated with a syringe. If drip collection is preferred, the animal will need to be placed in lateral recumbency. Twenty-one- or 22-gauge 1.5-inch styleted spinal needles are adequate for use in all but the largest-sized dogs. Occasionally, a 2.5- to 3-inch needle will be necessary on giant breeds. For extremely small animals, 23- to 25-gauge "butterfly" needles with attached tubing can be very useful if an assistant is available to aspirate the fluid.

**CSF Analysis and Interpretation.** Routinely, CSF is analyzed for color and turbidity, protein content, total red (RBC) and white blood cell (WBC) counts, and the differential cell count. In addition, it is wise to try to culture the CSF if a bacterial or fungal etiology is suspected or if organisms are seen on cytologic examination.

In general, elevations in protein content and WBC count are seen in CNS inflammatory diseases. These increases will vary with the type of organism involved and the duration of the inflammatory process. Meningeal involvement seems to cause greater increases in both protein and cell count than pure parenchymal involvement. 72

**Protein Content.** Viral diseases seem to cause the least amount of protein elevation, with the exception of the FIP virus, which can cause marked increases in protein. 51, 93 Bacterial, fungal, protozoal, and parasitic diseases cause moderate to marked elevations in protein. 72 Rickettsial diseases can have normal to minimal increases in CSF protein in Rocky Mountain spotted fever (RMSF) 11, 39, 40 compared with moderate to marked increases in ehrlichiosis. 10, 40 Cases of granulomatous meningoencephalomyelitis (GME) display mild to moderate (40 to 110 mg per dl) elevation of protein. 3, 10

**Cell Changes.** Viral diseases generally cause slight to moderate pleocytosis (15 to 60 WBC per mm³) that is primarily mononuclear (lymphocytes and macrophages) in nature. 73 If collected in the acute stages of viral disease, however, CSF may have neutrophilic pleocytosis and appear more like a bacterial meningitis. 50 Feline infectious peritonitis again proves to be the general exception, routinely displaying moderate to marked elevations of a mixed population of WBCs, including significant numbers of neutrophils. 72, 73

Bacterial infections cause the most dramatic elevation in WBCs. A high percentage of WBCs are neutrophils early in the inflammatory process. 10, 73 As the disease progresses, a mixed population of neutrophils and mononuclear cells (primarily macrophages) may be seen.

Fungal diseases commonly present with moderate to marked elevations of a mixed population of mononuclear and polymorphonuclear cells. 10, 73 Protozoal diseases usually present with a moderate pleocytosis of mixed mononuclear and polymorphonuclear cells. Parasitic diseases display moderate to marked mixed mononuclear-polymorphonuclear pleocytosis, often with a significant percentage of eosinophils.
Rickettsial diseases have been reported to have normal to markedly increased cell counts.\textsuperscript{10, 11, 40} The cells are reported to be mainly mononuclear in nature; however, in one report of RMSF, a great number of neutrophils (80 per cent) were present.\textsuperscript{40} Eosinophilic pleocytosis has been reported in human RMSF.\textsuperscript{21} Granulomatous meningoencephalitis usually has a moderate to marked number of mononuclear cells (lymphocytes, monocytes, macrophages) present in CSF.\textsuperscript{3, 10, 73}

**CSF Culture.** Culture of CSF is difficult and often unrewarding, even when organisms can be seen on cytologic examination. Enriched media and special incubation techniques are usually required for successful culture of CSF.\textsuperscript{36} Attempts to culture CSF should probably be reserved for those cases with increased protein content and neutrophilic pleocytosis (suspected bacterial involvement). Because of the frequency of false-negative CSF culture results and the rapidly progressive course of bacterial meningitis, antimicrobial therapy should not be delayed pending culture and sensitivity results.

**Blood and Urine Cultures**

Meningoencephalomyelitis can arise secondary to hematogenous spread of organisms from other organ system infections, such as bacterial endocarditis or urinary tract infection. Aseptically obtained blood, urine, and other tissue samples as indicated (tracheal wash, lung aspirate, and so on) can be cultured and often provide more definitive information about the cause of meningoencephalomyelitis than CSF cultures. It is advisable to collect these samples at the same time CSF is collected in the hopes of identifying the organism as rapidly as possible and, thus, expediting correct antimicrobial therapy.

**Serologic Tests**

Serologic tests exist for *Brucella canis*, canine distemper virus (CDV), FIP, toxoplasmosis, rickettsial organisms, and fungal organisms. In my experience, FIP, toxoplasmosis, and fungal titers are extremely unreliable. To date, rickettsial titers out of the University of Illinois\textsuperscript{*} and University of Georgia\textsuperscript{†} laboratories have proved to be the most reliable.

The most helpful serologic tests are for *Brucella canis* and CDV. A number of tests are available for *Brucella canis*; some are more sensitive than others. False-positive and false-negative results are possible depending on the test used. For this reason, two or more of the tests are often performed before making a final determination. Test results should always be interpreted in light of the clinical findings.\textsuperscript{39}

Canine distemper virus titers should be performed on serum and CSF simultaneously. Serum may have an increase in anti-CDV antibody from vaccination or natural infection. Because antibody is produced locally, an increase in CSF anti-CDV antibody (appearing 2 to 3 weeks after onset of disease) can occur only after CDV encephalitis and provides definite

\textsuperscript{*}Dr. Ristic, University of Illinois, Veterinary Diagnostic Medicine, P.O. Box U, Urbana, Illinois 61801.

\textsuperscript{†}Dr. Craig E. Greene, University of Georgia Rocky Mountain Spotted Fever Laboratory, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602.
evidence that the virus has been present in the CNS. Increased CSF anti-CDV antibody has not been demonstrated in vaccinated dogs or in dogs with systemic disease without CNS involvement. Blood contamination may artificially increase the anti-CDV titer in the CSF but should be suspected at the time of collection or CSF analysis. The laboratory at Auburn University has provided the most reliable results in my experience.

Skull Radiographs

If otitis interna/media is suspected as the cause of meningoencephalitis, skull films of the tympanic bullae may help in making the diagnosis. Sclerosis or lysis of an osseous bulla, increased density of a bulla cavity, or asymmetry of the bullae would all be suggestive of otitis interna/media. When meningoencephalitis is suspected secondary to cranial trauma, skull radiographs may help confirm the diagnosis.

Electroencephalography

Electroencephalography (EEG) is not an extremely helpful diagnostic test in CNS inflammatory disease. The findings may be abnormal but are nonspecific and do not assist in identification of the causative agent, selection of a therapeutic protocol, or prediction of the outcome.

Other Tests

Ear Cultures. If otitis interna/media is suspected as the source of the etiologic agent in meningoencephalitis, cultures of the middle ear may be helpful. These are extremely difficult to obtain without secondary contamination but may prove helpful in selecting correct antimicrobial therapy.

Fluorescent Antibody Testing for CDV. If performed during the time clinical infection is apparent, this test can be helpful in confirming the presence of CDV. Results are usually negative after the recovery stage begins and may even be negative during the infected stage. Consequently, negative results should not be used to rule out CDV.

THERAPY

Antimicrobial Agents

Antimicrobial agents are ideally selected based on specificity of action against the causative organism, bactericidal tendencies, accessibility to the site of infection, rapid action, and lack of undesirable side effects. When dealing with CNS inflammatory disease, accessibility becomes a critical problem owing to the natural barriers (primarily blood-brain and blood-CSF) against passage of drugs into the CNS. Drugs with a low degree of ionization, a low degree of plasma protein binding, and a high degree of lipid solubility in the un-ionized state are favored to enter the CNS because of increased membrane solubility. In addition, inflammatory damage may

---

*Dr. Larry Swango, Department of Microbiology, Auburn University College of Veterinary Medicine, Auburn, Alabama 36843.*
Table 1. Effectiveness of Antimicrobials in CNS Inflammatory Conditions

| Good Penetration | ACTION      | ROUTE | ORGANISMS |
|------------------|-------------|-------|-----------|
| Chloramphenicol  | Bacteriostatic | PO    | +, −      |
| Isoniazid        | Bacteriostatic | PO    | m         |
| Metronidazole    | Bactericidal  | PO    | a         |
| Pyrimethamine    | Bacteriostatic | PO    | p         |
| Rifampin         | Bacteriostatic | PO    | +, −, m, f|
| Sulfonamides     | Bacteriostatic | PO    | +, −, p   |
| Trimethoprim     | Bacteriostatic | PO    | +, −      |
| Trimethoprim-sulfamethoxazole | Bactericidal | PO    | +, −, p   |

| Intermediate Penetration (improved during inflammation) | ACTION     | ROUTE | ORGANISMS |
|---------------------------------------------------------|------------|-------|-----------|
| Amoxicillin                                             | Bactericidal | PO    | +, −, a   |
| Ampicillin                                              | Bactericidal | IV    | +, −, a   |
| Carbenicillin                                           | Bactericidal | IV    | +, −, a   |
| Cephalosporins                                          | Bactericidal | IV    | +, −, a   |
| First-generation                                        | Bactericidal | IV    | +, −, a   |
| Second-generation                                       | Bactericidal | IV    | −         |
| Third-generation                                         | Bactericidal | IV    | −         |
| Doxycycline                                             | Bactericidal | PO, IV| +, −, a   |
| Flucytosine                                             | Bactericidal | PO    | f         |
| Methicillin                                             | Bactericidal | IV    | +         |
| Minocycline                                             | Bactericidal | PO, IV| +, −, a   |
| Nafcillin                                               | Bactericidal | IV    | +         |
| Oxacillin                                               | Bactericidal | IV, PO| +         |
| Penicillin G                                            | Bactericidal | IV    | +         |
| Tetracyclines                                           | Bactericidal | PO, IV| +, −, a   |
| Vancomycin                                              | Bactericidal | IV    | +         |

| Poor Penetration | ACTION     | ROUTE | ORGANISMS |
|------------------|------------|-------|-----------|
| Aminoglycosides  | Bactericidal | IV, IT| +, −, m   |
| Amphotericin B   | Bacteriostatic | IV, IT| f         |
| Cephalosporins   | Bacteriostatic | PO, IV| +, −      |
| Erythromycin     | Bacteriostatic | PO    | +         |
| Ketoconazole     | Bacteriostatic | PO    | f         |
| Lincomycin       | Bacteriostatic | IM    | +, −, a   |

Key: + = gram-positive bacteria; − = gram-negative bacteria; a = anaerobic bacteria; m = mycobacteria; f = fungal organisms; p = protozoal organisms.

increase the CNS concentration of some drugs by increasing membrane permeability to the drugs or slowing their removal from the CSF (Table 1).72

Bacterial Infections. Bacterial infections of the CNS are rapidly progressive and fatal if not treated aggressively. When bacterial infection is suspected, antibiotic therapy should be started immediately. Changes can be made later based on culture results or lack of response to therapy. High-dose intravenous bactericidal therapy is preferred to obtain the highest CSF concentrations of the most efficacious drug(s) as rapidly as possible. Bactericidal and bacteriostatic drugs should not be combined because of reduced efficacy.

The most commonly reported organisms causing bacterial meningoencephalomyelitis in companion animals are Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus albus, Pasteurella multocida, Pasteu-
Inflammatyory Disease of the Central Nervous System

Rella species, Actinomyces species, and Nocardia species. Initial therapy should begin with the assumption that Staphylococcus is the most likely cause. High doses of intravenous (IV) penicillin G (10,000 to 20,000 U per kg every 4 to 6 hours), IV ampicillin (5 to 10 mg per kg every 6 hours), or oral (PO) amoxicillin (10 mg per kg every 8 hours) have been recommended. Ampicillin and amoxicillin are preferred to penicillin G because of their broader spectrum of activity. If the causative organism proves to be a coagulase-positive Staphylococcus, medication can be changed to methicillin. Oxacillin can be used for penicillin-resistant staphylococci. Carbenicillin is the drug of choice for Pseudomonas infection.

It is tempting to begin therapy with chloramphenicol, believing that high concentrations achieved in CSF can overcome the disadvantage of being bacteriostatic. However, many strains of Staphylococcus have been shown to be resistant to this drug, and it has demonstrated poor efficacy against gram-negative organisms. It is probably best to use chloramphenicol when the organism has been determined to be sensitive or as a second-choice drug. Chloramphenicol and penicillin are antagonistic and should not be used simultaneously unless deemed absolutely necessary. When used together, penicillin administration should precede chloramphenicol by at least 24 hours.

Trimethoprim-sulfonamide in combination is bactericidal. Both drugs penetrate the CNS barriers well. Together they have a relatively broad spectrum of activity. This combination should be kept in mind if initial treatment does not seem effective.

Metronidazole (10 to 15 mg per kg orally every 8 hours) penetrates the CNS well and is effective against anaerobic organisms. Penicillin and carbenicillin are probably more commonly used for CNS anaerobic infections, but metronidazole has proved effective.

Rifampin and isonizid are antituberculosis (Mycobacterium tuberculosis) drugs that reach significant levels in the CSF. Rifampin (10 to 20 mg per kg orally every 8 to 12 hours) has additional activity against Staphylococcus and some gram-negative bacteria and has been shown to enhance the antifungal effect of amphotericin B.

Aminoglycosides and penicillins are synergistic in combination. However, aminoglycoside penetration into the CNS is so poor that the only justification for its use in bacterial meningoencephalomyelitis is to treat a non-CNS source of infection. Intrathecal (IT) administration of gentamicin every 6 hours has been advocated to overcome the CNS barriers. However, the disadvantages of this approach probably outweigh the advantages in the majority of cases.

In general, tetracyclines are not useful for treatment of CNS inflammation because they penetrate poorly, are bacteriostatic, and have a more limited spectrum. However, the newer lipid-soluble second-generation tetracyclines (minocycline and doxycycline) penetrate the CNS and have better activity against anaerobes and certain aerobic organisms. Minocycline in combination with streptomycin has proved very effective against Brucella canis infection.

In general, cephalosporins penetrate the CNS poorly. However, there are conflicting reports on the ability of some of the relatively
toxic first-generation cephalosporins (cephaloridine, cephalothin, cephalaxin) to enter the CNS during times of inflammation. Some of the second- (cefamandole and cefoxitin) and third-generation (cefoxatine and moxalactam) cephalosporins have been shown to penetrate the CSF in sufficient levels to kill most organisms encountered. However, these drugs have demonstrated variable success in clinical settings.

To achieve the highest possible CSF levels as rapidly as possible, high-dose antibiotic therapy should be administered IV if possible for 1 to 2 weeks and then followed with oral medication. Antibiotic therapy should be continued for at least 4 weeks if treatment is to be successful. Very often, longer periods of administration will be required and relapses are possible.

Glucocorticoids, in combination with antibiotics, have been recommended to reduce tissue inflammatory response in cases of meningocerebralitis. Because of the difficulty of getting microcidal levels of antimicrobials into the CNS, successful treatment of bacterial and fungal meningocerebralitis depends on the body’s ability to mobilize its natural defense mechanisms to assist in removal of the causative agents. Doses of glucocorticoids sufficient to reduce cerebral edema are immunosuppressive and have been associated with increased morbidity, mortality, and relapses. Most authors agree that osmotic diuretics should be used instead of glucocorticoids if cerebral edema is deemed significant enough to require treatment.

**Fungal Infections.** Central nervous system fungal infections are difficult and usually unrewarding to treat. The disease is often multisystemic and seldom recognized in the early stages of CNS involvement. Combinations of antimicrobial agents seem to be more efficacious than individual drug therapy. Amphotericin B, flucytosine, and ketoconazole are the main agents used, none of which penetrate the CNS well. Rifampin, which does penetrate the CNS, has been shown to enhance amphotericin B activity. Most therapeutic regimens begin with amphotericin B (0.15 to 0.50 mg per kg IV every 2 days; 0.22 mg per kg gradually increased to 0.75 mg per kg 3 times weekly to a total dose of 7 to 20 mg per kg) and add flucytosine or ketoconazole. Intrathecal amphotericin B (0.1 to 0.5 mg IT every 2 to 3 days to a total of 10 to 15 mg) has been advocated to increase the concentration of the drug in CSF.

Flucytosine and amphotericin B act synergistically in vitro against Cryptococcus neoformans. This combination does not seem to have as good an effect in cases of coccidioidomycosis, probably because IV amphotericin B does not reach high enough levels to be effective. Therefore, IT amphotericin B is recommended for Coccidioides immitis infections. Ketoconazole may be effective against Candida species, Coccidioides immitis, Histoplasma capsulatum, and Cryptococcus neoformans, but it penetrates the CNS poorly. Its use is probably more beneficial for systemic rather than CNS fungal involvement. Rifampin in combination with amphotericin B seems to be most helpful against Histoplasma capsulatum. None of these drugs work well against Aspergillus species, but amphotericin B combined with flucytosine or rifampin should be tried.
Newer-generation imidazoles are currently under investigation that appear to reach significant levels in the CSF during inflammation. When approved, these drugs may offer new hope in the treatment of fungal meningoencephalomyelitis.

**Viral Infections.** No effective treatments are known for the viral nervous system diseases. At best we can offer good nursing care and support against secondary bacterial invaders. Glucocorticosteroids may lessen some of the clinical signs but also suppress the natural defense mechanisms that are the body's only mechanism of overcoming viral infection.

Antiviral drugs are of great interest but, to date, have proved quite toxic when given systemically. Viruses seem to be susceptible only during replication, which has usually occurred by the time the diagnosis is made. In general, these drugs are not currently of practical usefulness in viral diseases of companion animals.

No treatment should be attempted in cases of rabies and pseudorabies because of the risk to public health. Megadoses of vitamins and intravenous modified live vaccine have not proved beneficial in cases of canine distemper. Immunosuppressive drugs (glucocorticoids, melphan, cytoxan) have been used in cats with FIP with poor long-term results. Increasing the environmental temperature of puppies afflicted with neonatal canine herpesvirus may lower mortality.

Meningoencephalitis caused by canine parainfluenza virus has been reported clinically and experimentally. The importance of canine parainfluenza virus in naturally occurring neurologic disorders remains to be determined. No treatment is currently known.

Parvovirus and coronavirus/parvovirus vaccines have been incriminated as the causes of neurologic dysfunction in puppies. Signs of meningoencephalitis were seen in four puppies shortly after diagnosis of parvovirus enteritis. Parvovirus was isolated from the brain of a puppy that died of a severe necrotizing vasculitis and encephalomalacia without clinical signs of enteritis. Eight puppies were reported to have neurologic signs following vaccination with a canine coronavirus-parvovirus vaccine. In these reports, treatments were not described and all puppies died.

**Rickettsial Infections.** Ehrlichiosis (Ehrlichia canis), Rocky Mountain spotted fever (Rickettsia rickettsii), and salmon poisoning disease (Neorickettsia helminthoea) have been reported to cause encephalitis in companion animals. However, these diseases are more commonly associated with other clinical signs (pyrexia, petechiation, anemia, lymphadenopathy, splenomegaly, and so on). Lyme disease (Borrelia burgdorferi) has been identified in animals. Limb and joint disorders are the main clinical signs reported in dogs, but neurologic involvement has been reported in human beings and should be watched for in animals.

Tetracyclines and chloramphenicol have been shown to be effective against rickettsial organisms but are bacteriostatic. Elimination of the organisms from the body depends on the immunocompetence of the animal. The use of chloramphenicol is not advised in anemic animals but can be preferable in young dogs to avoid tetracycline staining of the teeth. Supportive therapy will vary among individual cases but may include fresh blood or platelet-rich plasma transfusions, bone marrow stimulants, fluid
therapy, and appetite stimulants. Doxycycline has proved more effective than oxytetracycline in the treatment of ehrlichiosis. Being a lipid-soluble tetracycline, doxycycline has better penetration into the CNS and should be preferred in cases with CNS involvement.

**Protozoal Infections.** Protozoal infections of the CNS are rare in companion animals. Toxoplasmosis, babesiosis, encephalitozoonosis, trypanosomiasis, and an amebic meningoencephalitis have been reported. Treatment of these conditions has variable results with a generally guarded to poor prognosis.

Pyrimethamine and sulfadiazine in combination are more effective against CNS toxoplasmosis than trimethoprim-sulfonamide. Folinic acid should be simultaneously administered to combat pyrimethamine-induced bone marrow suppression. Medications used to treat systemic toxoplasmosis have limited effectiveness (chloramphenicol) or do not penetrate into the CNS well (tetracycline, clindamycin).

Imidocarb dipropionate, diminazene aceturate, and phenamidine isethionate (aromatic diamidines) are suggested for canine babesiosis. Imidocarb dipropionate is also effective against *Ehrlichia canis*. Two intramuscular injections of 5 mg per kg of imidocarb dipropionate given 14 days apart seem effective against *Babesia canis* and *Ehrlichia canis*. No drug has been completely successful in clearing *Babesia gibsoni*. A single dose of primaquine phosphate intramuscularly (0.5 mg per kg) is recommended for feline babesiosis (*Babesia felis*).

Lithium antimony thiomalate and nifurtimox (8 to 30 mg per kg per day orally for 3 to 5 months) have been recommended for treatment of trypanosomiasis. No treatment exists for encephalitozoonosis. Acanthamoeba castellani was diagnosed histopathologically in an immunosuppressed puppy with rapidly fulminating meningoencephalitis. Acanthamoeba species have also been reported to cause meningoencephalitis in human beings.

**Parasitic Infections.** Parasites rarely cause CNS damage in companion animals. *Dirofilaria immitis* and *Cuterebra* species larvae are the most frequently reported. Parasitic involvement should be suspected if a pleocytic CSF is present with a high percentage of eosinophils. *Dirofilaria immitis* may be suspected if blood tests are positive. There are no definitive tests for the presence of *Cuterebra* larvae. These conditions are usually diagnosed on postmortem examination; therefore, successful treatments are rarely described. Successful surgical removal of extramedullary larvae is possible.

Other suspected and confirmed parasitic infections of the CNS have been reported. A cat with acute neurologic signs and CSF eosinophilic pleocytosis was reported to recover following therapy with levamisole. A confirmatory diagnosis of the etiology could not be made. Granulomatous encephalomyelitis caused by *Angiostrongylus cantonensis* has been reported in puppies. *Trypanosoma evansi* was confirmed as the cause of meningoencephalitis in dogs.

**Protothecal Infections.** Protothecosis is an extremely rare cause of CNS inflammation in companion animals. No successful treatments have been reported.
Steroid-Responsive Meningitis

Multisystemic polyarteritis (necrotizing vasculitis) involving the meninges has been reported. All dogs displayed clinical signs characteristic of meningitis (pyrexia, pain, and cervical rigidity); the majority of these dogs were relatively young animals.\textsuperscript{41, 43, 47, 65} In two of the reports in which related dogs were involved, CSF revealed a neutrophilic pleocytosis and elevated protein content; a peripheral neutrophilia was present.\textsuperscript{41, 65} Steroids were used in these dogs and caused transient to long-lasting improvement. No organisms were identified, and all authors suspected an immune-mediated cause of the vasculitis.

Two reports of 13 young dogs with corticosteroid-response meningitis parallel the clinical and laboratory findings reported in the cases with confirmed polyarteritis.\textsuperscript{64, 80} Only one of these dogs underwent pathological examination after 6 months of intermittent steroid administration. Chronic active suppurative leptomeningitis and leptomeningeal fibrosis were reported, but nothing specific was said about the meningeal vessels. An immune mechanism was suspected in all these dogs.

Granulomatous Meningoencephalitis/Reticulosis

Numerous cases of a nonsuppurative inflammatory disease with focal or diffuse CNS lesions have been reported in dogs\textsuperscript{1, 3, 8-10, 20, 22, 49, 69, 72, 73, 81, 101} but only rarely in cats.\textsuperscript{111} Ocular involvement has also been reported.\textsuperscript{59, 30, 35, 96} The term “reticulosis” was formerly used to describe what is now called disseminated GME (inflammatory reticulosis), focal GME (neoplastic reticulosis) and ocular GME (ocular reticulosis). Clinical signs reflect the focal, multifocal, or diffuse nature of CNS involvement. Focal GME most commonly involves the brain stem, whereas disseminated GME is usually widespread, especially in the cerebrum, lower brain stem, cerebellum, and cervical cord. The cause is unknown, but an immunologic basis is suspected.

Signalment is nonspecific and clinical signs can be acute or chronic progressive, varying with the sites of CNS involvement. CSF has a mild to moderate (40 to 110 mg per dl) elevation in protein and a moderate to marked (50 to 660 WBC per mm\textsuperscript{3}) mononuclear pleocytosis (lymphocytes, monocytes, macrophages). Temporary clinical improvement may be seen with glucocorticoid therapy, but no effective treatment is known.

Polioencephalomyelitis in Cats

A chronic progressive syndrome of ataxia, paresis, tremors, pupillary abnormalities, and seizures has been reported in cats of varying breeds and ages.\textsuperscript{42, 102} The pathology was suggestive of a viral cause, but organisms could not be demonstrated. The lesions were very similar to lesions reported in lions and tigers in which a viral cause was also suspected but never confirmed.\textsuperscript{33} Other similar cases have been reported.\textsuperscript{52, 63}

Chronic Encephalitis of Pug Dogs

A chronic progressive granulomatous meningoencephalitis causing diffuse degeneration of white matter and less often gray matter has been
reported in Pug dogs 9 months to 4 years of age.\textsuperscript{23} The clinical signs predominantly relate to cerebral lesions (generalized seizures, ataxia, paresis, circling, depression, partial motor seizures, visual deficits with intact pupillary reflexes). Central vestibular, cerebellar, and spinal cord signs have also been reported. Death is usually preceded by status epilepticus. Cerebrospinal fluid shows elevated protein content and a moderate elevation of lymphocytes and other mononuclear cells. Viral isolation has been unsuccessful, leaving the etiology unknown. A familial predisposition warrants investigation. There is no specific treatment known. Seizures are often refractory to anticonvulsants, and corticosteroids have not proved helpful.

**Eosinophilic Meningoencephalitis in a Cat**

A cat with neurologic signs including disorientation, inability to stand, visual and hearing losses, and seizures displayed mild CSF pleocytosis (17 WBC per mm\(^3\)) with 81 per cent eosinophils and a mild elevation in CSF protein (24 mg per dl). The cause was suspected to be a type I hypersensitivity reaction. The cat was successfully treated with dexamethasone.\textsuperscript{86}

**PROGNOSIS**

Diagnostic findings in CNS inflammatory disease may vary widely between different animals affected with the same etiologic agent, often making diagnosis and choice of therapy extremely difficult. Many of these diseases can only be positively confirmed through pathologic examination. The prognosis in any CNS inflammatory disease must be considered guarded to poor, even when there seems to be response to therapy. Temporary remissions and relapses are common.

**SUMMARY**

Inflammatory diseases involving the central nervous system can be difficult to diagnose and frustrating to treat. The clinician can maximize successful treatment of these patients by recognizing the clinical signs in the early stages of disease, following a logical diagnostic plan to identify the specific etiologic agent involved, and formulating an appropriate and aggressive therapeutic plan. Treatment will not always be successful owing to lack of effective treatments and irreversible neurologic damage.

**REFERENCES**

1. Alley MR, Jones BR, Johnstone AC: Granulomatous meningoencephalomyelitis of dogs in New Zealand. NZ Vet J 31:117, 1983
2. Bailey CS, Higgins RJ: Comparison of total white blood cell count and total protein content of lumbar and cisternal cerebrospinal fluid of healthy dogs. Am J Vet Res 46:1162, 1985
3. Bailey CS, Higgins RJ: Characteristics of cerebrospinal fluid associated with canine
granulomatous meningoencephalomyelitis: A retrospective study. J Am Vet Med Assoc 188:418, 1986
4. Bateman DE, White JE, Ellington G, et al: Three further cases of Lyme disease. Br Med J 594:548, 1987
5. Baumgartner WK, Metzler AE, Krakowka S, et al: In vitro identification and characterization of a virus isolated from a dog with neurological dysfunction. Infect Immun 31:1177, 1981
6. Baumgartner WK, Krakowka S, Koestner A, et al: Acute encephalitis and hydrocephalus in dogs caused by canine parainfluenza virus. Vet Pathol 19:79, 1982
7. Bestetti G, Buhlmann V, Nicolet J, et al: Paraplegia due to Actinomyces viscosus infection in a cat. Acta Neuropathol 39:231, 1977
8. Braund KG, VanDevelde M, Walker TL, et al: Granulomatous meningoencephalomyelitis in six dogs. J Am Vet Med Assoc 172:1195, 1978
9. Braund KG: Granulomatous meningoencephalomyelitis. J Am Vet Med Assoc 186:138, 1985
10. Braund KG: Clinical Syndromes in Veterinary Neurology. Baltimore, Williams & Wilkins, 1986
11. Breitschwerdt EB, Meuten DJ, Walker DH, et al: Canine Rocky Mountain spotted fever: A kennel epizootic. Am J Vet Res 46:2124, 1985
12. Broderick JP, Sandok BA, Mertz LE: Focal encephalitis in a young woman 6 years after the onset of Lyme disease: Tertiary Lyme disease? Mayo Clin Proc 62:313, 1987
13. Bullmore CC, Sevedge JP: Canine meningoencephalitis. J Am Anim Hosp Assoc 14:387, 1978
14. Carithers RW, Nichols CE, Whitney KM: Meningoencephalitis as a sequel to parvovirus in 4 dogs. (personal communication)
15. Chew M: Canine meningoencephalitis due to Trypanosoma evansi infection: A report of two cases. Vet Rec 82:663, 1968
16. Cook JR Jr, Tyler DE, Coulter DB, et al: Disseminated protothecosis causing acute blindness and deafness in a dog. J Am Vet Med Assoc 184:1266, 1984
17. Cook JR Jr, Levesque DC, Nuehring LP: Intracranial cuterebral myiasis causing acute lateralizing meningoencephalitis in two cats. J Am Anim Hosp Assoc 21:279, 1985
18. Cooley AJ, Clemmons RM, Gross TL: Heartworm disease manifested by encephalomyelitis and myositis in a dog. J Am Vet Med Assoc 190:431, 1987
19. Cordes DO, Royal WA: Cryptococcosis in a cat. NZ Vet J 15:117, 1967
20. Cordy DR: Canine granulomatous meningoencephalomyelitis. Vet Pathol 16:325, 1979
21. Crennan JM, Van Scoy RE: Eosinophilic menigitis caused by Rocky Mountain spotted fever. Am J Med 80:298, 1986
22. Cuddon PA, Smith-Maxie L: Reticulosus of the central nervous system in the dog. Compend Contin Ed Pract Vet 6:23, 1984
23. de Lahunta A: Veterinary Neuroanatomy and Clinical Neurology. Edition 2. Philadelphia, WB Saunders Co, 1983
24. Donahoe JMR, Holzinger EA: Dirofilaria immitis in the brains of a dog and a cat. J Am Vet Med Assoc 154:515, 1974
25. Dunbar M Jr, Pyle RL, Boring JG, et al: Treatment of canine blastomycosis with ketoconazole. J Am Vet Med Assoc 182:156, 1983
26. Edwards NJ, Rebhun WC: Generalized cryptococcosis: A case report. J Am Anim Hosp Assoc 15:439, 1979
27. Evermann JF, Lincoln JD, McKeirnan AI: Isolation of a paramyxovirus from the cerebrospinal fluid of a dog with posterior paresis. J Am Vet Med Assoc 177:1132, 1980
28. Fenner WR: Treatment of central nervous system infections in small animals. J Am Vet Med Assoc 185:1176, 1984
29. Fischer CA, Liu SK: Neuro-ophthalmic manifestations of primary reticulosus of the central nervous system in a dog. J Am Vet Med Assoc 158:1240, 1971
30. Fischer CA, Jones FT: Optic neuritis in dogs. J Am Vet Med Assoc 160:68, 1972
31. Fisher LS, Chow AW, Yoshikawa TT, et al: Cephalothin and cephaloridine therapy for bacterial meningitis. Ann Intern Med 82:689, 1975
32. Fiske RA, Choyce PD, Whitford HW, et al: Phaeohyphomycotic encephalitis in two dogs. J Am Anim Hosp Assoc 22:327, 1986
33. Flir K: Encephalomyelitis bei gross katzen. DTW 80:393, 1973
34. Fukushima K, Hutsell D, Patton S, et al: Aberrant dirofilariasis in a cat. J Am Vet Med Assoc 184:199, 1984
35. Garmer NL, Maeser P, Bergman AJ: Reticulosis of the eyes and the central nervous system in a dog. J Small Anim Pract 22:39, 1981
36. Gearhart MA, de Lahunta A, Summers BA: Cerebellar mass in a dog due to granulomatous meningoencephalitis. J Am Anim Hosp Assoc 22:683, 1986
37. Gelatt KN, McGill LD, Pernan V: Ocular and systemic cryptococcosis in a dog. J Am Vet Med Assoc 162:370, 1973
38. Graybill JR, Williams DM, Cutsem EV, et al: Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis 2:551, 1980
39. Greene CE: Clinical Microbiology and Infectious Diseases of the Dog and Cat. Philadelphia, WB Saunders Co, 1984
40. Greene CE, Burgdorfer W, Cavagnolo R, et al: Rocky Mountain spotted fever in dogs and its differentiation from canine ehrlichiosis. J Am Vet Med Assoc 186:465, 1985
41. Harcourt RA: Polyarteritis in a colony of beagles. Vet Rec 102:519, 1978
42. Hoff EJ, Vandevelde M: Non-suppurative encephalomyelitis in cats suggestive of a viral origin. Vet Pathol 7:170, 1981
43. Hoff EJ, Vandevelde M: Case report: Necrotizing vasculitis in the central nervous systems of two dogs. Vet Pathol 18:219, 1981
44. Jang SS, Biberstein EL, Rinaldi MG, et al: Feline brain abscesses due to Cladosporium trichoides. Sabouraudia 15:115, 1977
45. Jergens AE, Wheeler CA, Colliver LL: Cryptococcosis involving the eye and central nervous system of a dog. J Am Vet Med Assoc 189:302, 1986
46. Johnson BJ, Castro AE: Isolation of canine parvovirus from a dog brain with severe necrotizing vasculitis and encephalomalacia. J Am Vet Med Assoc 184:1398, 1984
47. Kelly DF, Grunsell CSG, Kenyon CJ: Polyarteritis in the dog: A case report. Vet Rec 92:363, 1973
48. Koestner A, Zeman W: Primary reticulosis of the central nervous system in animals. Acta Neuropathol Suppl VI:85, 1975
49. Kornblatt AN, Urband PH, Steere AC: Arthritis caused by Borrelia burgdorferi in dogs. J Am Vet Med Assoc 186:960, 1985
50. Kornegay IN, Lorenz MD, Zenoble RD: Bacterial meningoencephalitis in two dogs. J Am Vet Med Assoc 173:1334, 1978
51. Kornegay IN: Feline infectious peritonitis: The central nervous system form. J Am Anim Hosp Assoc 14:550, 1978
52. Kornev T, Nordstrom M, Moreno W, et al: Feline ataxia due to nonsuppurative meningoencephalomyelitis of unknown aetiology. Nord Vet Med 26:720, 1974
53. Landesman SH, Corrado ML, Prasad MS, et al: Fast and current roles for cephalosporin antibiotics in treatment of meningitis. Am J Med 71:693, 1981
54. Legendre AM, Whitenack DL: Feline infectious peritonitis with spinal cord involvement in two cats. J Am Vet Med Assoc 167:931, 1975
55. Legendre AM, Gompf R, Bone D: Treatment of feline cryptocoecosis with ketoconazole. J Am Vet Med Assoc 181:1541, 1982
56. Luttgen PJ, Crawley RW: Posterior paralysis caused by epidural dirofilariasis in a dog. J Am Anim Hosp Assoc 17:57, 1981
57. Magnarelli LA, Anderson JF, Kaufmann AF, et al: Borreliosis in dogs from southern Connecticut. J Am Vet Med Assoc 186:955, 1985
58. Mandelker L, Brutus RL: Feline and canine dirofilarial encephalitis. J Am Vet Med Assoc 159:776, 1971
59. Mason KV, Prescott CW, Kelly WR, et al: Granulomatous encephalomyelitis of puppies due to Angiostrongylus cantonensis. Aust Vet J 52:295, 1976
60. Mayhew IG, Beal CR: Techniques of analysis of cerebrospinal fluid. Vet Clin North Am 10:155, 1980
61. McEwen SA, Hulland TJ: Cerebral blastomycosis in a cat. Can Vet J 25:411, 1984
62. McKenzie BE, Lyles DI, Clinkscales JA: Intracerebral migration of cuterebra larva in a kitten. J Am Vet Med Assoc 172:173, 1978
63. Melchior G: Meningo-encephalitis beim Lowen und Tiger in Erkrankungen der Zootiere, Verhandlungsbericht des XV. Internationalen Symposiums über die Erkrankungen
64. Meric SM, Perman V, Hardy RM: Corticosteroid-responsive meningitis in ten dogs. J Am Anim Hosp Assoc 21:677, 1985
65. Meric SM, Child G, Higgins RJ: Necrotizing vasculitis of the spinal pachyleptomeningeal arteries in three Bernese Mountain Dog littermates. J Am Anim Hosp Assoc 22:459, 1986
66. Moellering RC, Swartz MN: The newer cephalosporins. N Engl J Med 294:24, 1976
67. Mullaney DT, John JF: Cefotaxime therapy: Evaluation of its effect on bacterial meningitis, CSF drug levels, and bactericidal activity. Arch Intern Med 143:1705, 1983
68. Mullaney TP, Levin S, Indrieri RJ: Disseminated aspergillosis in a dog. J Am Vet Med Assoc 182:516, 1985
69. Murtaugh RJ, Fenner WR, Johnson GC: Focal granulomatous meningoencephalomyelitis in a pup. J Am Vet Med Assoc 187:835, 1985
70. Nafe LA, Turk JB, Carter JD: Central nervous system involvement of blastomycosis in the dog. J Am Anim Hosp Assoc 19:933, 1983
71. Nasisse MP, van Ee RT, Wright B: Ocular changes in a cat with disseminated blastomycosis. J Am Vet Med Assoc 187:829, 1985
72. Oliver JE Jr, Lorenz MD: Handbook of Veterinary Neurologic Diagnosis. Philadelphia, WB Saunders Co, 1983
73. Oliver JE Jr, Hoerlein BJ, Mayhew IG: Veterinary Neurology. Philadelphia, WB Saunders Co, 1987
74. Pal M, Merhotra BS: Studies on the occurrence of cryptococcal meningitis in small animals. Mykosen 28:607, 1985
75. Pearce JR, Powell HS, Chandler FW, et al: Amebic meningoencephalitis caused by Acanthamoeba castellani in a dog. J Am Vet Med Assoc 187:951, 1985
76. Percy DH, Olander HJ, Carmichael LE: Encephalitis in the newborn pup due to a canine herpesvirus. Pathol Vet 5:135, 1968
77. Pryor WH, Huizenga CF, Splitter GA, et al: Coccioidoides immitis encephalitis in two dogs. J Am Vet Med Assoc 161:1108, 1972
78. Reik L Jr, Smith L, Khan A, et al: Demyelinating encephalopathy in Lyme disease. Neurology 35:267, 1985
79. Rhoades HE, Reynolds HA, Rahn DP, et al: Nocardiosis in a dog with multiple lesions of the central nervous system. J Am Vet Med Assoc 142:278, 1963
80. Russo EA, Lees GE, Hall CL: Corticosteroid-responsive aseptic suppurative meningitis in three dogs. Southwestern Vet 35:197, 1983
81. Russo ME: Primary reticulosis of the central nervous system in dogs. J Am Vet Med Assoc 174:492, 1979
82. Rutgers CR, Kowalski J, Cole CR, et al: Severe Rocky Mountain spotted fever in five dogs. J Am Anim Hosp Assoc 21:361, 1985
83. Sarfaty D, Carrillo JM, Greenlee PG: Differential diagnosis of granulomatous meningoencephalomyelitis, distemper, and suppurative meningoencephalitis in the dog. J Am Vet Med Assoc 188:387, 1986
84. Sartin EA, Hendrix CM, Killehay DL, et al: Cerebral cuterebrosis in a dog. J Am Vet Med Assoc 189:1338, 1986
85. Schaer M, Johnson KE, Nicholson AC: Central nervous system disease due to histoplasmosis in a dog: A case report. J Am Anim Hosp Assoc 19:311, 1983
86. Schultze AE, Cribb AE, Twedten HW: Eosinophilic meningoencephalitis in a cat. J Am Anim Hosp Assoc 22:623, 1986
87. Sedmak PA: Babesia. Part I. Epidemiology, pathogenesis, and diagnosis. Compend Contin Ed Pract Vet 5:521, 1983
88. Sedmak PA: Babesia. Part II. Prophylaxis and control. Compend Contin Ed Pract Vet 6:49, 1984
89. Segedy AK, Hayden DW: Cerebral vascular accident caused by Dirofilaria immitis in a dog. J Am Anim Hosp Assoc 14:752, 1978
90. Sevedge JP: Canine meningoencephalitis. J Am Anim Hosp Assoc 14:387, 1978
91. Shadduck JA, Benedele R, Robinson GT: Isolation of the causative organism of canine meningoencephalitozoonosis. Vet Pathol 15:449, 1978
92. Shell LC, Ely RW, Crandell RA: Pseudorabies in a dog. J Am Vet Med Assoc 178:1159, 1981
93. Sherding RG: Feline infectious peritonitis. Compend Contin Ed Pract Vet 1:95, 1979
94. Shinwari MW, Thomas AD, Orr JS: Feline cerebral phaeohyphomycosis associated with Cladosporium bantianum. Aust Vet J 62:383, 1985
95. Slatter DH: Fundamentals of Veterinary Ophthalmology. Philadelphia, WB Saunders Co, 1981
96. Smith JS, de Lahunta A, Riis RC: Reticulosis of the visual system in a dog. J Small Anim Pract 18:643, 1977
97. Sutton RH: Cryptococcosis in dogs: A report on 6 cases. Aust Vet J 57:558, 1981
98. Szabo JR, Shadduck JA: Experimental encephalitozoonosis in neonatal dogs. Vet Pathol 24:99, 1987
99. Tyler DE, Lorenz MD, Blue JL, et al: Disseminated protothecosis with central nervous system involvement in a dog. J Am Vet Med Assoc 176:987, 1980
100. van den Hoven E, McKenzie RA: Suspected paecilomycosis in a dog. Aust Vet J 50:368, 1974
101. Vandevelde M, Kristensen B, Greene CE: Primary reticulosis of the central nervous system in the dog. Vet Pathol 15:673, 1978
102. Vandevelde M, Braund KG: Polioencephalomyelitis in cats. Vet Pathol 16:420, 1979
103. Vandevelde M: Primary reticulosis of the central nervous system. Vet Clin North Am 10:57, 1980
104. Visvesvara GS, Mirra SS, Brandt FH, et al: Isolation of two strains of Acanthamoeba castellani from human tissue and their pathogenicity and isoenzyme profiles. J Clin Microbiol 18:1405, 1983
105. Wagner JL, Pick JR, Krigman MR: Cryptococcus neoformans infection in a dog. J Am Vet Med Assoc 153:945, 1968
106. Weder B, Wiedersheim P, Matter L, et al: Chronic progressive neurological involvement in Borrelia burgdorferi infection. J Neurol 234:40, 1987
107. Whitley RD, Nelson SL: Pseudorabies (Aujeszky's disease) in the canine: Two atypical cases. J Am Anim Hosp Assoc 16:69, 1980
108. Wilkinson GT: Feline cryptococcosis: A review and seven case reports. J Small Anim Pract 20:749, 1979
109. Wilson RB, Holladay JA, Cave JS: A neurologic syndrome associated with use of a canine coronavirus-parvovirus vaccine in dogs. Compend Contin Ed Pract Vet 8:117, 1986
110. Wright NG, Cornwell HJC: Experimental herpesvirus infection in young puppies. Res Vet Sci 9:295, 1968
111. Zaki FA, Nafe LA: Ischemic encephalopathy and focal granulomatous meningoencephalitis in the cat. J Small Anim Pract 21:429, 1980

Department of Small Animal Medicine and Surgery
College of Veterinary Medicine
Texas A&M University
College Station, Texas 77843